|
07.01.2025 13:09:00
|
Bright Minds Biosciences Appoints Stephen Collins As CMO
(RTTNews) - Bright Minds Biosciences, Inc. (DRUG), a company focused on drug-resistant epilepsy, depression, and other central nervous system disorders, said on Tuesday that it has appointed Stephen D. Collins as Chief Medical Officer with immediate effect.
The company has also announced that Mark A. Smith will retire from his role as Acting CMO but will continue to serve in an advisory capacity.
Prior to joining Bright Minds, Collins simultaneously served as CEO of Biscayne Neurotherapeutics and CEO of Biscayne Pharmaceuticals, which was sold to Supernus Pharmaceuticals in 2018.
Nachrichten zu Bright Minds Biosciences Inc Registered Shs Reg S Accred Inv
| Keine Nachrichten verfügbar. |
Analysen zu Bright Minds Biosciences Inc Registered Shs Reg S Accred Inv
Im BX Morningcall werden folgende Aktien analysiert und erklärt:
NEU✅ Wolters Kluwer
NEU✅ American Express
NEU✅ Deckers Outdoor
inklusive Rebalancing:
❌ Synopsys
❌ Vertex Pharmaceuticals Inc
❌ Targa Resources
👉🏽 https://bxplus.ch/bx-musterportfolio/
Inside Trading & Investment
Mini-Futures auf SMI
Inside Fonds
Meistgelesene Nachrichten
Börse aktuell - Live Ticker
SMI schließlich höher -- DAX letztlich stabil -- Wall Street bleibt geschlossen -- Asiens Börsen schliessen im MinusDer heimische Aktienmarkt bewegte sich am Donnerstag höher, während der deutsche Aktienmarkt nahe der Nulllinie notierte. An der Wall Street findet am Donnerstag kein Handel statt. In Asien verbuchten die Börsen am Donnerstag Verluste.
finanzen.net News
| Datum | Titel |
|---|---|
|
{{ARTIKEL.NEWS.HEAD.DATUM | date : "HH:mm" }}
|
{{ARTIKEL.NEWS.BODY.TITEL}} |